Investigating how the SKIDA1 gene affects the development of acute myeloid leukemia.
Official title: The Role of SKIDA1 in Acute Myeloid Leukemia Initiation and Maintenance
Funded at Washington University · NIH-10913288 · Data updated 2026-11-12
This study is looking at how a specific gene called SKIDA1 affects the development of acute myeloid leukemia (AML) in infants, using mouse models to see what happens when this gene is removed, which could help find new ways to treat this type of leukemia.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 1, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $34,926 |
| NIH project number | 5F31CA268923-02 |
| Project ID | NIH-10913288 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are infants and children diagnosed with acute myeloid leukemia, particularly those with MLL1 gene rearrangements.
✕Less likely to help
Patients with acute myeloid leukemia who do not have MLL1 gene rearrangements may not benefit from this research.
What this research studies
This research focuses on understanding the role of the SKIDA1 gene in the initiation and maintenance of acute myeloid leukemia (AML), particularly in infants. The study examines how MLL fusion proteins, which are linked to AML, interact with neonatal hematopoietic progenitor cells to promote leukemia. By using mouse models, researchers will explore the effects of deleting the SKIDA1 gene on blood cell development and leukemia progression. This could provide insights into potential therapeutic targets for treating AML.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating acute myeloid leukemia in infants and children.
How similar studies have gone: Previous research has shown promising results in understanding the genetic factors involved in leukemia, making this approach both relevant and potentially impactful.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Mendoza-Castrejon, Jonny — Washington University
- Study coordinator: Mendoza-Castrejon, Jonny
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.